home / stock / acxp / acxp articles
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholder...
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) shares are trading lower after the company released efficacy results from a Phase 2 trial. ...
NEW YORK, Oct. 20, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a national TV show, announces episode 524th airing on the Fox Bus...
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indic...
Gainers OpGen, Inc. (NASDAQ: OPGN) jumped 593% to $2.33 following two SEC filings from the precision medicine company. The company has received a...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares are blasting higher Thursday and have gained more than 300% over the last five days. What To Know...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares surged Monday. The company recently announced the successful completion and early discontinuation...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its national business TV show airing on Bloomberg TV as sponsored programming tonight, Thursday, June 6, 2024, at 9:30 PM PT. New to The Street's TV episode 576 will air the follo...
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection PR Newswire Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial program Agreement al...
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biophar...